Synaptic dysfunction and loss are core pathological features in Alzheimer disease (AD). In the vicinity of amyloid-b plaques in animal models, synaptic toxicity occurs and is associated with chronic activation of the phosphatase calcineurin (CN). Indeed, pharmacological inhibition of CN blocks amyloid-b synaptotoxicity. We therefore hypothesized that CN-mediated transcriptional changes may contribute to AD neuropathology and tested this by examining the impact of CN over-expression on neuronal gene expression in vivo. We found dramatic transcriptional down-regulation, especially of synaptic mRNAs, in neurons chronically exposed to CN activation. Importantly, the transcriptional profile parallels the changes in human AD tissue. Bioinformatics analyses suggest that both nuclear factor of activated T cells and numerous microRNAs may all be impacted by CN, and parallel findings are observed in AD. These data and analyses support the hypothesis that at least part of the synaptic failure characterizing AD may result from aberrant CN activation leading to down-regulation of synaptic genes, potentially via activation of specific transcription factors and expression of repressive microRNAs.
Calcium homeostasis dysregulation is an important component of neurotoxicity in Alzheimer disease (AD) and may underlie many of the neurotoxic effects of amyloid b (Ab) (Mattson and Chan 2003; Supnet and Bezprozvanny 2010; Woods and Padmanabhan 2012; Popugaeva et al. 2017) . Elevation of cytosolic calcium is triggered by Ab oligomers (Shankar et al. 2007; Kuchibhotla et al. 2008; Wu et al. 2010; Sep ulveda et al. 2014; Arbel-Ornath et al. 2017) , leading to downstream activation of many pathways, including the calcium/calmodulin-dependent serine/threonine-phosphatase calcineurin (CN, or protein phosphatase 2B) (Kuchibhotla et al. 2008; Wu et al. 2010; Mohmmad Abdul et al. 2011; Spires-Jones et al. 2011) . Ab-mediated calcineurin activation may have multiple mechanisms impacting the synapse, involving both direct dephosphorylation of cytoplasmic substrates such as GSK3b, cofilin, and AKAP79 (Zhou et al. 2004; Bhattacharyya et al. 2009; Hern andez et al. 2010; Jurado et al. 2010; Kamat et al. 2016) as well as activation of transcription factors. CN dephosphorylates four of the five members of the nuclear factor of activated T cells (NFAT) transcription factor family (NFATc1, NFATc2, NFATc3, and NFATc4), all of which are activated by calcium-mediated signaling, inducing nuclear translocation, and activation of target genes associated with neuronal survival, axonal outgrowth, and dendritic arborization (Benedito et al. 2005; Nguyen and Di Giovanni 2008; Schwartz et al. 2009; Serrano-P erez et al. 2015) . Increased NFAT localization in the nucleus is observed in brains from AD patients or from neurons derived from transgenic mice harboring amyloid precursor protein mutations (Abdul et al. 2009; Wu et al. 2010) , and NFAT blockade diminishes Ab-induced dendritic spine loss in mice (Hudry et al. 2012) suggesting the activation of an NFATmediated transcriptional program in AD. By and large, most differentially expressed genes in AD tissue are downregulated (Berchtold et al. 2013 ) which has generally been attributed to loss of neurons. However, down-regulation in AD may be a consequence of transcriptional repression rather than an artifact of cell loss; indeed, NFAT can act as a powerful transcriptional repressor in neurons (Nguyen et al. 2009 ). The study herein aims to clarify the transcriptional role of the CN and/or NFAT pathway in neurons as it relates to gene down-regulation in AD.
To directly test the hypothesis that CN activation contributes to synaptic dysfunction in AD, we asked whether the pattern of genes altered by CN in neurons was similar to changes observed in AD. However, CN-related gene alterations have not been previously explored in neurons in vivo. We therefore first expressed CN and constitutively activated CN (caCN) in hippocampal neurons in the mouse brain, using adeno-associated virus (AAV) transduction. This construct has previously been shown to increase translocation of NFAT to the nucleus and lead to NFAT-mediated transcription as measured by luciferase assay (Hudry et al. 2012) . Truncated versions of CN is observed in the human AD brain, including versions lacking the auto-inhibitory Cterminal domain leading to constitutive activation of CN targets (Liu et al. 2005; Wu et al., 2010; Mohmmad Abdul et al., 2011) ; therefore AAV-mediated chronic caCN likely mimics the effects one might see in the context of AD. We then compared the pattern of gene expression changes following caCN activation with those previously reported to occur in human cases of AD. In mouse hippocampal neurons, CN led to substantial down-regulation of numerous transcripts, especially those related to synaptic physiology. This pattern had striking overlap with the pattern of changes observed in AD brain, supporting the hypothesis that CN activation contributes to synaptic dysfunction in AD. Furthermore, CN activation overall mediated a substantial down-regulation in gene expression which we found may be related to activation of a large number of micro-RNAs (miRNAs), many of which are also expressed in AD, suggesting a potential mechanism for the overall transcriptional down-regulation which we observed.
Materials and methods

Animals
In vivo experiments were performed on 3-to4-month-old adult male C57BL/6J mice (the Jackson Laboratory, Bar Harbor, ME, USA, stock #00064, RRID:IMSR_JAX:000664) weighing 22-25 g. Animals were socially housed with environmental enrichment (igloos) at 3-4 mice per cage with ad libitum access to food and water on a 12/12 light/dark cycle. Experiments were approved by the Massachusetts General Hospital Institutional Animal Care and Use Committee (protocol #2004N000092) and carried out in accordance with the Massachusetts General Hospital Subcommittee on Research Animal Care following guidelines set forth by the National Institutes of Health Guide for the Care and Use of Laboratory Animals. The study was not pre-registered.
Viral vectors construction and production
The constructions of AAV-CBA-HA-caCN and AAV-CBA-HAwtCN backbones were previously described (Wu et al. 2010) . Briefly, CaNwt and CaNCA (amino acid residues 1-399) were subcloned into AAV-cytomegalovirus/chicken b-actin (CBA)-woodchuck post-transcriptional regulatory element (WPRE) vector. The caCN construct includes amino acid residues 1-399, excluding the auto-inhibitory domain. As a control, we used a green fluorescent protein (GFP) virus, AAV-CBA-GFP, that was available at the Harvard Gene Therapy Core. AAV serotype 2 vectors were produced after triple-transfection of HEK293 cells and genome copy titers were determined by qRT-PCR by the Harvard Gene Therapy Core. All the constructs were verified by sequencing. We confirmed that the coding sequence of the two CN constructs were not complementary to the Affymetrix Mouse Genome 430 Array probe sequences for CN using Basic Local Alignment Search Tool (Altschul et al. 1990) . While the AAV promoter was the general promoter CBA, the AAV serotype 2 has selective tropism for neurons (Taymans et al. 2007; Watakabe et al. 2015; Choudhury et al. 2017) .
Stereotactic intrahippocampal injections
Stereotactic intrahippocampal injections of AAV serotype 2 vectors were performed as described previously (Hudry et al. 2012) . During the day in the laboratory surgical suite, animals were anesthetized by intraperitoneal injection of ketamine/xylazine (100 mg/kg and 50 mg/kg body weight, respectively) and positioned on a stereotactic frame (David Kopf Instruments, Tujunga, CA, USA). Ketamine/xylazine was chosen as it is considered relatively safe in mice and achieves effective analgesia, muscle relaxation, and sedation. Injections of vectors were performed in the hippocampus of each hemisphere with 3 lL of viral preparation (titer 2 9 10 12 vg/mL) using a 30-gauge sharp micropipette attached to a 10-lL Hamilton syringe (Hamilton Medical, Reno, NV, USA) at a rate of 0.2 lL/min. The hippocampus was chosen because of its pathological targeting in AD. Stereotactic coordinates of injection sites were calculated from bregma to target the hippocampus (anteroposterior À2 mm, mediolateral AE1.7 mm and dorsoventral À2 mm). To avoid the confounding factor of the injury from injection and viral immune activation (Lowenstein and Castro 2003) , we used both a nonviral (phosphate-buffered saline, PBS) and viral (GFP) controls.
Injections of each group occurred on different days to prevent repeated freeze-thaw cycles of the virus; therefore, there was no specific randomization for injection order. Mice were treated with buprenorphine (Buprenex Injection, #7571, 0.05 mg/kg) subcutaneously immediately following surgery and given access to Tylenol water (Gericare, New York, NY, USA, NDC 57896-180-16, 10 mL into 250 mL of water) for the 3 days following surgery for analgesia; mice were monitored for appropriate recovery from surgery. The sample size was evaluated using the sample size calculators from Massachusetts General Hospital Biostatistics Center (http://hedwig.mgh.harvard.edu/sample_size/ size.html). We estimated that six samples per group were needed to detect a difference in means of 30% and taking into account a standard deviation of the outcome variable of 0.1 (power set at 0.8 and a significance level of 0.05). An overall experimental outline is illustrated in Fig. 1(a) .
Euthanasia, tissue processing, and laser capture One month after injection with AAVs, mice were euthanized by CO 2 asphyxiation. Brains were dissected and snap frozen in liquid nitrogen. Sections (10 lm) were generated on a cryostat, mounted on Gold Seal slides and stored at À80°C for a few days before immunostaining and microdissection. After a short fixation step in cold acetone (1 0 ), staining for HA (Mouse monoclonal anti-HA antibody; Biolegend, Dedham, MA, USA, #901513, RRID: AB_2565335) or GFP (Rabbit anti-GFP; Abcam, Cambridge, MA, USA, #ab6556, RRID:AB_305564) was performed on ice following a rapid protocol to preserve the RNA integrity (15 0 incubation with the primary antibodies and 10 0 with appropriate Alexa-488 conjugated secondary antibodies). An average of 460 pyramidal neuronal cell bodies positive for either HA or GFP were dissected and collected mostly from hippocampal CA3/CA1 pyramidal neurons and DG granule neurons using laser capture (Fig. 1b) ; the order of collection was randomized by mouse treatment group (simple randomization method). After RNA extraction using the Arcturus â PicoPure â Frozen RNA Isolation Kit (ThermoFisher Scientific, Walthan, MA, USA, #KIT0214), RNA quality and quantification was assessed using the Agilent RNA 6000 Pico Kit (Agilent Technologies, Santa Clara, CA, USA, # 5067-1513). From the samples collected, 6-7 samples per condition (PBS, AAV-GFP, AAV-caCN, AAV-wtCN) were sent for microarray analysis after testing for expression of the AAV transgene by qPCR (Fig. 1b) . To examine expression of only AAV expressed CN and not endogenous CN, we used primers at the junction of the CN cassette and the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element 
Microarray statistical analysis
Gene expression was measured using a GeneChip â High-throughput Perfect Match Array Mouse Genome 430 (HT MG-430 PM Array; Affymetrix, Santa Clara, CA, USA, # 901258). Treatment groups were de-identified and replaced with numbers rather than names prior to samples being sent for microarray quantification as to blind the analysis; groups were identified following initial data analysis. Microarray data were first normalized using robust multichip average (Bolstad et al. 2003; Irizarry et al. 2003) using the justRMA Bioconductor package for R (https://www.bioconductor.org/packa ges/devel/bioc/manuals/affy/man/affy.pdf). The mean expression of technical replicates was computed for each sample. Principal component analysis (PCA) was performed to identify outlying samples, none were found. Surrogate variable analysis was used to remove unwanted variation in the data (Leek and Storey 2007) ; then differentially expressed genes were identified between the groups using the limma package in R (Ritchie et al. 2015) with an adjusted pvalue cut-off of 0.05 and an absolute value fold-change cut-off of 2 using the Benjamini-Hochberg procedure. Ensembl release 89 0 s
BioMart was used to find human orthologs for the mouse genes (Yates et al. 2016) . Functional categories of the differentially expressed genes were determined using DAVID EASE ). Finally, the gene set enrichment analysis software (Subramanian et al. 2005 ) was used to compute enrichment of AD and NFAT/CN related gene sets, which were identified using the keywords 'Alzheimer', 'NFAT', and 'Calcineurin' (Subramanian et al. 2005) .
For genes with multiple microarray probes, data are reported as the probe that has the maximum difference in the experiment for each gene. All transcript names are reported as human gene orthologs.
Expression analysis of MSBB_Human_Hippocampus_B3_B1 dataset
RNA expression data were obtained from the Accelerating Medicines Partnership Alzheimer Disease knowledge portal (found at https://www.synapse.org/#!Synapse:syn2580853/). The human hippocampus dataset was downloaded from the Mount Sinai Brain Bank (MSBB) AD Cohort. The MSBB raw data underwent correction for covariates such as sex, PMI, pH, and race prior to download and our downstream analysis; this original information can be obtained from the Accelerating Medicines Partnership Alzheimer Disease database directly. The 33 samples were grouped by a neuropathological score assessing the distribution of tau neurofibrillary tangles in the subject's brain (Braak and Braak 1991) . This analysis compared RNA expression observed in a group of Braak stages V/VI subject brain tissues with that observed in a group of normal and Braak stage I/II subject brains (Table 1) . Analysis was performed using the Limma package in R (Ritchie et al. 2015) . No prior filtering on probes was performed, neither on variance nor intensity.
GTEx, determination of hippocampus expressed genes GTEX_HIPPOCAMPUS_EXPRESSED_GENES_FPKM10 includes genes expressed with a median FPKM value of 10 or greater in the 123 human hippocampus samples polyA+ RNAsequenced by the Genotype-Tissue Expression (GTEx) Project. GTEX_HIPPOCAMPUS_EXPRESSED_GENES_FPKM1 is the same, however, the cut-off is FPKM value of 1 or greater. The GTEx Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. The data used for the analyses described above were obtained from the GTEx Portal on 05/17/17.
Results
Sustained calcineurin expression after AAV intrahippocampal injection
One month following intracortical injection of the AAVs (Fig. 1a) , brains were sectioned, and cells stained for HA (to detect CN) or GFP. Robust staining of neuronal cell bodies was observed in the pyramidal cell layers of the hippocampus (CA3). To further confirm AAV transduction with CN, we measured expression of CN at the junction of the WPRE [which can detect both wild-type calcineurin (wtCN) and caCN but not endogenous CN] in the injected mice (Fig. 1b) . Samples for which RNA quality and CN expression were verified were sent for further gene expression profiling. We specifically chose hippocampal CA3/CA1 pyramidal neurons and DG granule neurons based on location and cell morphology to ensure that we were only examining CNassociated changes in neurons. We confirmed the expression of AAV-mediated CN expression by qPCR (Fig. 1c) using primers designed to avoid detection of endogenous CN as described in the Methods section above and only used samples for further analysis that demonstrated expression of CN.
Over-expression of caCN or wtCN induces similar changes gene expression patterns in vivo
To have a general appreciation of the data dispersion between experimental groups (AAV-caCN, AAV-wtCN, AAV-GFP, and PBS-injected mice), a principal component analysis of the Affimetrix data was initially performed (PCA; Fig. 2a ). The caCN (blue) and wtCN (green) specimens cluster separately from the control samples (pink and red). Interestingly, we observed striking overlap between the gene expression patterns induced by wtCN (green) and caCN (blue), thus suggesting that over-expression of CN is sufficient to induce robust transcriptional changes, regardless of the presence of the auto-inhibitory subunit. We speculate that AAV transduction may lead to so much over-expression of wtCN, that there is essentially a 'ceiling effect', leading to effectively identical gene expression patterns between wtCN and caCN. The lack of differences between wtCN and caCN groups is illustrated by volcano plot in Fig. 2(b) . This is in . In contrast with the relative similar transcriptional profiles of caCN and wtCN expressing neurons, a large differential expression is observed between the GFP and PBS samples due the effect of AAV injections; the volcano plot in Fig. 2 (c) demonstrates these changes. Approximately 400 genes are differentially expressed between GFP and PBS controls using the same cut-offs; several of which of are ribosomal genes. Previous literature on the transcriptional impact of AAV transduction is relatively sparse, but a handful of studies have been reported, showing in particular that AAV serotype 2 could elicit an ER stress response and trigger UPR signaling pathways in HeLA cells, a phenomenon less prominent after single-stranded AAV2 transduction (Balakrishnan et al. 2013) . Other literature reports immune pathways activated by AAV (McCaffrey et al. 2008; Zhu et al. 2009) , although the AAV host responses likely vary upon the serotype, the injection route and the transduced cells. We did not observe increases in any of these previously reported pathways between PBS and GFP controls (data not shown).
Since no additional information appears to explain these similarities, as well as the changes between results from the comparison of wtCN and caCN, and because it is evident that the GFP control (which involves injection and expression of AAV) provides a type of control more appropriate for these analyses than PBS injection, we decided to analyze the gene expression alterations between caCN and GFP controls only. We chose the GFP as the control group to control for AAVand protein over-expression-induced differences between the two groups.
Constitutively active CN induces broad changes in gene expression, involving synaptic targets and others We then compared caCN to the AAV-GFP-injected control group. Differential expression level of specific human gene orthologs is demonstrated by volcano plot (Fig. 2d) . Of 45 141 mouse gene probes assessed by the microchip, a total of 1529 genes probes were differentially expressed in caCN versus GFP control with an adjusted p-value cut-off of 0.05 and an absolute value fold-change cut-off of 2 (Table S1 ), which when converted to human gene orthologs was 1166 out of 15 611 genes that were differentially expressed between caCN and GFP control. Functional categories of the differentially expressed genes, determined using DAVID EASE ), included synapse (p = 1.67E-12), membrane (p = 8.61E-15), and ion channel (p = 4.11E-04) proteins; complete table is available in Table S2 . All of the top ten are downregulated by caCN (Table 2) , which is reflective of the overall dataset where approximately 90% of the differentially expressed genes are down-regulated. Furthermore, all the top 10 differentially expressed genes are expressed in or specific for brain tissue according to previous literature (Uhlen et al. 2015) .
We then performed GSEA on the caCN and GFP samples. The top 50 up-regulated and top 50 down-regulated features of the caCN and GFP samples determined by GSEA are displayed in the heatmap in Fig. 3 .
Calcineurin activated genes overlap with NFAT targets and genes expressed in late-stage AD To test the hypothesis that CN, via NFAT, triggers transcriptional changes in neurons analogous to the changes that occur in AD, GSEA was computed on 22 gene lists relevant to AD or NFAT and Calcineurin pathways. The results of GSEA are visualized using DOSE (Yu et al. 2015) in Fig. 4 (a) and (b) and effect sizes are listed in Table 3 . GSEA shows significant enrichment of hippocampal genes (GTEX_HIPPOCAMPUS_EXPRESSED_GENES_FPKM10), previously identified human hippocampal AD signature (Blalock et al. 2011 ) (BLALOCK_ALZHEIMERS_DISEA-SE_DN), human gene expression signature of late Braak stages computed using human hippocampal data from Mount Sinai Brain Bank (MSBB_Human_Hippocampus_B3_B1), and NFAT/Calcineurin/AD pathways obtained from MSigDB (Liberzon et al. 2015) . The NFAT computationally derived targets based on the promoter binding sequence TGGAAA (Xie et al. 2005 ) (TGGAAA_NFAT_Q4_01) was also significant as was the curated NFAT target set PID_NFAT_TFPATHWAY. The KEGG AD pathway impact by caCN is illustrated in Fig. 4(c) .
Next, we more closely examined the overlap of the curated NFAT target set PID_NFAT_TFPATHWAY, with genes differentially expressed in neurons with caCN overexpression (Fig. 4d) ; this pathway was largely upregulated by caCN. However, the computationally derived TGGAAA_NFAT_Q4_01 pathway was largely downregulated in caCN-treated animals; in fact, most of the differentially expressed genes in caCN compared to GFP control were down-regulated (see Table S1 ). We hypothesized that CN activation could suppress transcription via NFAT (Nguyen et al. 2009 ) or activation of suppressive elements such as microRNAs. We then performed GSEA on the MSigDB C3 collection of motif gene sets, including microRNA and transcription factor target sets (Table S3 ). 661 out of 836 gene sets were significantly (FDR q-value < 0.25) down-regulated in caCN-treated animals compared to GFP-treated animals and a large proportion of these are microRNA target sets (190 gene sets).
Discussion
Previous in vivo expression of a version of caCN in mouse forebrain neurons demonstrated profound induction of long term potentiation and memory deficits that is independent of gene transcription Winder et al. 1998) , although work from our group has demonstrated an important role of NFAT-mediated transcriptional effects on calcineurin-induced synaptotoxicty in vitro (Hudry et al. 2012) ; the study herein bridges this gap understanding by examining the transcriptional effects of CN in vivo. Indeed, an advantage of the methodology utilized here, in comparison with previously reported microarray analyses of CN activation, is the use of chronic in vivo viral transduction of CN activation as opposed to in vitro analysis of activation. Use of an in vivo system including microglia and astrocytes, which monitor the status of nearby neurons (Nimmerjahn et al. 2005; Dall erac et al. 2013) likely mediates many of the observed effects of CN expression in the study herein, although we have focused on the transcriptional activity in CA3 neurons alone. Only mRNA captured within neuronal cell bodies was analyzed because of the technical limitations of isolating neurons inclusive of their processes by laser microdissection; this caveat is important to recognize because of the presence of mRNA in both proximal and apical dendrites (Bramham and Wells 2007) , although we anticipate that by looking at the chronic timepoint of 4 weeks that an accurate snapshot of CN-induced transcriptional activity may be captured.
This study tested the hypothesis that increased CN activity via the transcription factor NFAT in neurons plays a causative role in AD pathology by examining the prediction that pathways associated with AD phenotypes, such as synaptotoxicity, would be altered when CN is activated. Statistical analysis of the microarray data overall support this hypothesis. The gene set enrichment data demonstrate a strong overlap between genes differentially regulated by caCN expression and gene pathways associated with synapses and AD as well as genes containing a computationally derived NFAT-responsive sequence. For example, synapse-related genes are dramatically and broadly downregulated in both AD and caCN over-expression, which is consistent with the synaptic dysfunction and loss observed in AD. Interestingly, many synapse-related genes have been reported to be part of a class of calcium regulated synapseassociated transcripts that have been observed to change in both normal aging, and, to a greater extent, in AD (Saetre et al. 2011) .
Nearly all of the differentially expressed genes in the microarray were similarly affected by transduction with wtCN or caCN; only Crh emerged as differentially expressed between the two forms of wtCN and caCN. The two control groups (PBS and GFP) were found to be well separated from the two CN treatment groups by PCA. It is of note that while the PCA plot revealed a distinct separation of the CN groups from the control groups, the CN groups themselves show essentially complete overlap. Indeed, we noted only one gene in the array that was differentially regulated between wtCN and caCN. This may be reflective of the sensitivity of the CN pathway to perturbation, in that over-expression of CN, regardless of its form, is sufficient to shift the balance of the basal functions of CN (Lam et al. 2009; Mukherjee and Soto 2011) . We also found that the Crh gene was slightly upregulated in human AD cases compared to controls. However, previous reports have shown that Crh gene expression is significantly down-regulated in AD (Blalock et al. 2003; Zhang et al. 2013) and is one of the top 20 most highly differentially expressed genes in AD brains compared to control brains . Studies in several model systems of AD have suggested that Crh plays a role in AD pathology and synaptotoxicity (Pedersen et al. 2001; Dong et al. 2012 Dong et al. , 2014 Filipcik et al. 2012) . These data add to a conflicting set of data associating Crh with synaptotoxicity and AD and highlights a need for studies directly examining the interplay between Crh and AD.
In contrast to the dramatic up-regulation of Crh, the analysis revealed that most of the transcripts differentially expressed between caCN and GFP controls were downregulated (1380 vs. 151); all of the top ten differentially expressed genes were down-regulated. Six of these top ten genes overlap with the BLALOCK_ALZHEIMERS_DI-SEASE_DN gene set as well as the GO_NEURON_PART gene set. Scamp1, one of the most significantly downregulated gene in the caCN group, has been identified by GWAS as having the potential of involvement with AD in a small cohort (Shulman et al. 2011 ) and its deletion is associated with neural defects in Drosophila similar to AD model phenotypes (Zheng et al. 2014) . Examination of the literature reveals that the many of the top gene hits are critical for neuronal synaptic function and are altered in AD and other dementias. Nceh1 protects against asynuclein toxicity (Zhang et al. 2017) and is decreased in blood samples drawn from AD patients (Mandas et al. 2012) ; its normal function involved homeostatic cholesterol regulation which is disrupted in AD (Sato and Morishita 2015) . Similarly, Tspan3 plays a role in membrane and cholesterol regulation as well as amyloid precursor protein processing and presenilin function (Seipold and Saftig 2016) . Rasgrf1 is necessary for dendritic spine formation (Detrait et al. 2014) , and is down-regulated in AD and prion diseases (Tian et al. 2014) . Sv2b is a synaptic vesicle protein that is down-regulated in the temporal pole of AD patients (Tan et al. 2010) . Psk1 regulates membrane morphology and microtubule binding during apoptosis, phosphorylates tau, and is present in tau tangles (Zihni et al. 2006; Tavares et al. 2013) . Atpgap2 is important in the AD-disrupted autophagy and lysosome functions (Colacurcio et al. 2017) and is down-regulated by caCN as well as in the Tg2576 AD mouse model (George et al. 2010) . These data support the hypothesis that CN triggers transcriptional changes associated with AD pathology which we further examined below by GSEA. Many of the other top genes differentially expressed by caCN are associated with AD (Ma et al. 2013; Tavares et al. 2013; Wei et al. 2014) . On a systems level, Fig. 4(c) demonstrates broad parallels between caCN-mediated transcriptional changes and those associated with late-stage AD. In particular, mitochondrial functional transcripts are disrupted in both, as are N-methyl-D-aspartate receptor and p25/ p35. Interestingly, Ano3, one of the top down-regulated genes by caCN, is vital to maintenance of the mitochondrial membrane potential and could be linked to the observed mitochondrial gene expression differences. Of note, one interpretation of the down-regulation of neuronal genes in AD is simply a loss of neurons, with concomitant change in cell landscape form bulk samples. In the current analysis, however, laser capture microdissection was used to capture intact neuronal cell bodies, which nonetheless showed this same pattern of down-regulation of most CN-responsive genes. This suggests that the downregulation in AD is a consequence of gene transcription, likely related to CN activation and NFAT related transcriptional repression rather than primarily because of neuronal loss. NFAT can act as a powerful transcriptional repressor in neurons (Nguyen et al. 2009 ) and we have demonstrated here that many genes (with computationally derived NFAT binding sites) are down-regulated (Fig. 4d) . It is relevant to note that some of those computationally generated genes with NFAT binding motifs may be false positives, not expressed in neurons, or require additional factors for activation. This down-regulation of CN-responsive transcripts in neurons is in contrast to work examining CNresponsive transcripts in cultured astrocytes, where the majority of transcripts observed were up-regulated (Norris et al. 2005) . These contrasting results suggest that CN may have dramatically different effects in different cell types, perhaps owing to expression of different downstream effectors, including different isoforms of NFAT.
In caCN neurons there was down-regulation of several miRNA-regulated gene sets by GSEA (Supplemental Table S3 ) which is in concordance with data from other groups demonstrating that several microRNAs are regulated by NFAT (Kang et al. 2013; Kannambath 2016) . Numerous miRNAs are associated with both induction of neurodegeneration and loss of neuroprotection in AD, via decreases in mir124 which normally suppresses b-secretase 1 and increases in mir34 which down-regulates various synaptic genes, respectively (Goodall et al. 2013; Reddy et al. 2017) . Both of these microRNA pathways were identified in GSEA analysis of MSigDB C3 motif gene sets, as well as several others that are altered in AD. Furthermore, the mir124 pathway, which was identified in the GSEA analysis of caCN, is capable of feeding back on NFAT and suppressing transcription via inhibition of elements of the transcriptional pathway. Spag9 and Tnpo1, both of which are regulated by mir124a and involve the NFAT pathway (Willingham et al. 2005) , were down-regulated in caCN-treated neurons. Tnpo1 encodes the protein importin b 1, which is necessary for NFAT translocation to the nucleus (Ishiguro et al. 2011) as well as translocation of several other transcription factors important to neuronal function including AP-1 and cAMP-response element binding protein (CREB) (Forwood et al. 2001) . Indeed, targets of the CREB pathway are down-regulated in caCN neurons (Table S3 ) and CREB signaling deficits are observed in AD (Saura and Valero 2011) . Furthermore, CN directly blocks pro-synaptic CREB via desphosphorylation and inactivation (Bito et al. 1996) .
We have interpreted these transcriptional changes as directly consequent to neuronal CN expression, but it is important to note that microglia and astrocytes monitor the status of nearby neurons (Nimmerjahn et al. 2005; Dall erac et al. 2013) and crosstalk between these cell types likely mediates some of the observed effects of CN expression. In accord with this caveat, it is clear that expression of CN in glia promotes numerous phenotypic changes that can impact neurons (Furman et al. 2016; Sompol et al. 2017 ) and the transcriptional response to CN in astrocytes includes upregulation of transcripts (Norris et al. 2005) in opposition to the down-regulation observed here, indicating important celltype specific differences in the CN pathway. Moreover, we postulate that neuroinflammatory signals may play a major role in neuronal and glial CN activation, potentially linking neuroinflammation to a specific molecular mechanism that affects the neurodegenerative phenotype.
Conclusions
Overall, this study indicates that chronic CN over-expression in neurons is sufficient to trigger a broad transcriptional program change, likely involving transcription factors NFAT, CREB, and micro-RNAs, leading to marked expression changes in genes associated with synapses and energy metabolism. The CN-responsive gene set is overwhelmingly biased to down-regulation, suggesting the possibility that CN-mediated transcriptional events like NFAT translocation acts largely as a transcriptional repressor in neurons. There is striking overlap between changes observed after chronic CN activation and those observed in AD, suggesting that dysregulation of CN homeostasis may be a major contributor to the marked transcriptional changes in synaptic genes and others observed in AD. Together with the previous observations that CN inhibition can improve synaptic morphology in mouse models of AD, these results are consistent with the possibility that CN inhibition may restore impact synaptic alterations in AD as well.
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